AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39054765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT: 80%-100% HRR)
Number of subjects: 121
Study 39054765 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Training (MIT: 60%-70% HRR)
Number of subjects: 121
Study 39054765 — intervention group
Group type: COMPARATOR
Intervention: Passive Control Group (CON)
Number of subjects: 121
Study 39054770 — intervention group
Group type: EXPERIMENTAL
Intervention: (2R,6R)-Hydroxynorketamine (RR-HNK) at doses of 0.1-4 mg/kg (SAD) and 1-2 mg/kg (MAD) administered via IV over 40 minutes
Number of subjects: 0
Study 39054770 — intervention group
Group type: EXPERIMENTAL
Intervention: (2R,6R)-Hydroxynorketamine (RR-HNK)
Number of subjects: 0
Study 39055378 — intervention group
Group type: EXPERIMENTAL
Intervention: Catenary curve-based extended depth of focus (EDOF) contact lens
Number of subjects: 24
Study 39055379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) therapy
Number of subjects: 22
Study 39055379 — intervention group
Group type: COMPARATOR
Intervention: Control Eye (CT)
Number of subjects: 22
Study 39055495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of utidelone and capecitabine
Number of subjects: 0
Study 39055495 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 0
Study 39055663 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral β-blocker therapy
Number of subjects: 1084
Study 39055663 — intervention group
Group type: COMPARATOR
Intervention: No β-blocker therapy (Control)
Number of subjects: 1084
Study 39055703 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug regimen (2DR) - dolutegravir or darunavir/cobicistat + lamivudine
Number of subjects: 100
Study 39055703 — intervention group
Group type: COMPARATOR
Intervention: Three-drug regimen (3DR) - integrase inhibitor-based
Number of subjects: 100
Study 39056160 — intervention group
Group type: EXPERIMENTAL
Intervention: IGU monotherapy (25 mg twice daily)
Number of subjects: 911
Study 39056160 — intervention group
Group type: EXPERIMENTAL
Intervention: IGU + MTX (10-15 mg weekly for MTX and 25 mg twice daily for IGU)
Number of subjects: 911
Study 39056160 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy (10-15 mg weekly)
Number of subjects: 911
Study 39056160 — intervention group
Group type: EXPERIMENTAL
Intervention: IGU monotherapy
Number of subjects: 911
Study 39056160 — intervention group
Group type: EXPERIMENTAL
Intervention: IGU + MTX
Number of subjects: 911
Study 39056338 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3427 (5, 15, or 45 mg)
Number of subjects: 48
Study 39056338 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3427 (subcutaneous injection)
Number of subjects: 48
Study 39056338 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3427
Number of subjects: 48
Study 39056338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 39056349 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg)
Number of subjects: 282
Study 39056349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 39057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Local recurrence (LR)
Number of subjects: 1965
Study 39057139 — intervention group
Group type: EXPERIMENTAL
Intervention: New metastatic disease (NM)
Number of subjects: 1965
Study 39057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor histological response (≥10% viable tumor)
Number of subjects: 1965
Study 39057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial tumor location
Number of subjects: 1965
Study 39057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lung metastases
Number of subjects: 1965
Study 39057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor versus good histological response
Number of subjects: 1965
Study 39057291 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line axitinib treatment
Number of subjects: 0
Study 39057551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 0
Study 39058022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin (intravenous)
Number of subjects: 0
Study 39058022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39058315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks
Number of subjects: 163
Study 39058315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 39058315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 163
Study 39058367 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily in continuous 28-day cycles)
Number of subjects: 19
Study 39058490 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% nicotine concentration (JUUL)
Number of subjects: 50
Study 39058490 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4% nicotine concentration (NJOY)
Number of subjects: 50
Study 39058490 — intervention group
Group type: COMPARATOR
Intervention: 5% nicotine concentration (JUUL or NJOY)
Number of subjects: 50
Study 39058490 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% or 2.4% nicotine concentration sessions
Number of subjects: 50
Study 39058662 — intervention group
Group type: EXPERIMENTAL
Intervention: QPOP-guided chemotherapy
Number of subjects: 10
Study 39058740 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A (BoNT-A) injection into calf muscles
Number of subjects: 61
Study 39058740 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline injection into calf muscles (placebo)
Number of subjects: 61
Study 39058806 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-etanercept
Number of subjects: 156
Study 39058806 — intervention group
Group type: COMPARATOR
Intervention: O-etanercept
Number of subjects: 156
Study 39058951 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine)
Number of subjects: 524
Study 39058951 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus immunochemotherapy (rituximab and bendamustine)
Number of subjects: 524
Study 39058951 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib plus R-B
Number of subjects: 524
Study 39058951 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus R-B
Number of subjects: 524
Study 39058954 — intervention group
Group type: EXPERIMENTAL
Intervention: IXA-POM-DEX
Number of subjects: 30
Study 39058954 — intervention group
Group type: COMPARATOR
Intervention: POM-DEX
Number of subjects: 30
Study 39058954 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover patients (from POM-DEX to IXA-POM-DEX)
Number of subjects: 30
Study 39058966 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) added to multidrug chemotherapy
Number of subjects: 268
Study 39058966 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 268
Study 39058966 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 268
Study 39058967 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application for education and symptom management
Number of subjects: 22
Study 39058968 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (2 cycles)
Number of subjects: 45
Study 39058968 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation (for 13 CNS lesions)
Number of subjects: 45
Study 39058968 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (for lesions with adequate interim response)
Number of subjects: 45
Study 39058972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vebreltinib
Number of subjects: 52
Study 39059033 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE
Number of subjects: 303
Study 39059184 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitor (CDK4/6i) therapy
Number of subjects: 2891
Study 39059184 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (upfront therapy)
Number of subjects: 2891
Study 39059187 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of linoleic acid derived sEH (DiHOME) and CYP450 (EpOME) metabolites
Number of subjects: 112
Study 39059187 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP450-sEH metabolites
Number of subjects: 112
Study 39059373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil cream, 3.6%
Number of subjects: 0
Study 39059373 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 39059389 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal cfEBV DNA tracking during neoadjuvant chemotherapy and radiotherapy
Number of subjects: 1000
Study 39059389 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal cfEBV DNA tracking
Number of subjects: 1000
Study 39059396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 13
Study 39059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Foritinib (80, 120, 160, or 210 mg orally once daily over 21-day cycles in phase 2a; 160 mg in phase 2b)
Number of subjects: 104
Study 39059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Foritinib (160 mg orally once daily in phase 2b)
Number of subjects: 104
Study 39059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Foritinib
Number of subjects: 104
Study 39059405 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCMA/GPRC5D bispecific CAR T cells
Number of subjects: 21
Study 39059407 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB078 (5 mg, 10 mg, 20 mg, 35 mg, 60 mg, or 90 mg)
Number of subjects: 106
Study 39059407 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB078 (any dose)
Number of subjects: 106
Study 39059407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 39059719 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion processing (face matching)
Number of subjects: 160
Study 39059719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control over emotion (shape matching)
Number of subjects: 160
Study 39059719 — intervention group
Group type: EXPERIMENTAL
Intervention: Age moderation
Number of subjects: 160
Study 39059719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactivation in the right inferior parietal lobe
Number of subjects: 160
Study 39059790 — intervention group
Group type: EXPERIMENTAL
Intervention: niPGT-A embryo culture protocol
Number of subjects: 428
Study 39059790 — intervention group
Group type: COMPARATOR
Intervention: Standard invasive PGT-A culture protocol
Number of subjects: 428
Study 39059804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy (laparoscopic surgery)
Number of subjects: 0
Study 39059887 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (wearable sensor alerts and self-testing)
Number of subjects: 450
Study 39059887 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (self-testing only due to symptoms)
Number of subjects: 450
Study 39059887 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (control group, no alerts or home testing)
Number of subjects: 450
Study 39060019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO+IPI)
Number of subjects: 1096
Study 39060019 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 1096
Study 39060022 — intervention group
Group type: EXPERIMENTAL
Intervention: TG6050 (oncolytic vaccinia virus encoding hIL-12 and anti-CTLA-4 antibody)
Number of subjects: 0
Study 39060125 — intervention group
Group type: EXPERIMENTAL
Intervention: TPG plus amantadine
Number of subjects: 100
Study 39060125 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus amantadine
Number of subjects: 100
Study 39060169 — intervention group
Group type: EXPERIMENTAL
Intervention: Veinlite PEDI2
Number of subjects: 160
Study 39060169 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 160
Study 39060169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 39060169 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including VR and Veinlite PEDI2)
Number of subjects: 160
Study 39060170 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise during nasal CPAP application
Number of subjects: 80
Study 39060170 — intervention group
Group type: COMPARATOR
Intervention: Routine nasal CPAP application
Number of subjects: 80
Study 39060172 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model-based motivational interviews, web support, and follow-up (experimental group)
Number of subjects: 63
Study 39060172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 39060370 — intervention group
Group type: EXPERIMENTAL
Intervention: AB002 1.5 µg/kg
Number of subjects: 36
Study 39060370 — intervention group
Group type: EXPERIMENTAL
Intervention: AB002 3 µg/kg
Number of subjects: 36
Study 39060370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 39060373 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning-based method that fuses multi-modality images
Number of subjects: 0
Study 39060373 — intervention group
Group type: COMPARATOR
Intervention: Commercially available software-PMOD
Number of subjects: 0
Study 39060374 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-8993 (fully human IgG1κ monoclonal antibody)
Number of subjects: 0
Study 39060374 — intervention group
Group type: COMPARATOR
Intervention: Human isotype IgG1 control
Number of subjects: 0
Study 39060374 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-8993
Number of subjects: 0
Study 39060473 — intervention group
Group type: EXPERIMENTAL
Intervention: HP6V (violet LED and 6% hydrogen peroxide)
Number of subjects: 40
Study 39060473 — intervention group
Group type: EXPERIMENTAL
Intervention: HP6B (blue LED and 6% hydrogen peroxide)
Number of subjects: 40
Study 39060473 — intervention group
Group type: EXPERIMENTAL
Intervention: HP35V (violet LED and 35% hydrogen peroxide)
Number of subjects: 40
Study 39060473 — intervention group
Group type: EXPERIMENTAL
Intervention: HP35B (blue LED and 35% hydrogen peroxide)
Number of subjects: 40
Study 39060689 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming chest masculinization surgery
Number of subjects: 0
Study 39060689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologic risk-reducing mastectomies
Number of subjects: 0
Study 39060701 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF membrane transplantation (PMT group, n=21)
Number of subjects: 40
Study 39060701 — intervention group
Group type: COMPARATOR
Intervention: Conventional internal limiting membrane (ILM) peeling (IP group, n=19)
Number of subjects: 40
Study 39060701 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF membrane transplantation (PMT group)
Number of subjects: 40
Study 39060701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 39060905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4362
Study 39060905 — intervention group
Group type: COMPARATOR
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 4362
Study 39060934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measurements on five cognitive domains (reasoning, working memory, processing speed, vocabulary, exploration) conducted in classrooms and at home
Number of subjects: 600
Study 39060934 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep phenotyping sessions including structural and functional MRI, eye-tracking, parental measurements, and questionnaire-based demographic and psychosocial measures
Number of subjects: 600
Study 39060934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of variability
Number of subjects: 600
Study 39060961 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long-course chemoradiation (LCRT)
Number of subjects: 760
Study 39060961 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long-course chemoradiation (LCRT)
Number of subjects: 760
Study 39060961 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant long-course chemoradiation (LCRT) followed by consolidation chemotherapy
Number of subjects: 760
Study 39060968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB)
Number of subjects: 40
Study 39060974 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy, Healthy, Loved text-message program
Number of subjects: 62
Study 39060974 — intervention group
Group type: COMPARATOR
Intervention: Usual care with attentional control text messages about infant development
Number of subjects: 62
Study 39061093 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist, liraglutide
Number of subjects: 40
Study 39061093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Number of subjects: 40
Study 39061093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 39061094 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 µM simvastatin
Number of subjects: 426
Study 39061094 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type C57BL/6J mice
Number of subjects: 426
Study 39061094 — intervention group
Group type: COMPARATOR
Intervention: Mice carrying a hypomorphic missense mutation in Zfp335
Number of subjects: 426
Study 39061099 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary total hip arthroplasty (THA)
Number of subjects: 0
Study 39061175 — intervention group
Group type: EXPERIMENTAL
Intervention: High monocyte counts
Number of subjects: 152
Study 39061175 — intervention group
Group type: COMPARATOR
Intervention: Low monocyte counts
Number of subjects: 152
Study 39061175 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD8 T-cell levels
Number of subjects: 152
Study 39061175 — intervention group
Group type: COMPARATOR
Intervention: High CD8 T-cell levels
Number of subjects: 152
Study 39061599 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood biomarker test for spontaneous preterm birth risk screening followed by preventive treatments for those screening positive.
Number of subjects: 0
Study 39061599 — intervention group
Group type: COMPARATOR
Intervention: Usual care in a clinically low-risk historical population.
Number of subjects: 0
Study 39062003 — intervention group
Group type: EXPERIMENTAL
Intervention: STP1 (combination of ibudilast and bumetanide)
Number of subjects: 12
Study 39062003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 39064048 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Number of subjects: 0
Study 39064048 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39065260 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-426 (10 µg)
Number of subjects: 0
Study 39065260 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-426 (2 µg and 5 µg)
Number of subjects: 0
Study 39065260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39066372 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent Omicron XBB.1.5-adapted BNT162b2 vaccine (30 μg)
Number of subjects: 40
Study 39066382 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix vaccine (GlaxoSmithKline Biologicals)
Number of subjects: 169
Study 39066382 — intervention group
Group type: COMPARATOR
Intervention: M-M-RII (Merck & Co.)
Number of subjects: 169
Study 39066382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (Priorix and M-M-RII)
Number of subjects: 169
Study 39066557 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-unit transcutaneous electrical nerve stimulation (Uno)
Number of subjects: 47
Study 39066557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual unit transcutaneous electrical nerve stimulation (Duo)
Number of subjects: 47
Study 39066557 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug use (Control)
Number of subjects: 47
Study 39066638 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day for 16 weeks
Number of subjects: 0
Study 39066638 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline hyclate 100 mg/day for 16 weeks
Number of subjects: 0
Study 39066638 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day
Number of subjects: 0
Study 39066638 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline hyclate 100 mg/day
Number of subjects: 0
Study 39066746 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign First Phase I treatment (CAT group)
Number of subjects: 41
Study 39066746 — intervention group
Group type: COMPARATOR
Intervention: Tooth-borne rapid maxillary expansion (RME group)
Number of subjects: 41
Study 39066758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic risk modeling with a multistate model
Number of subjects: 2056
Study 39066962 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 1972
Study 39066962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1972
Study 39066962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Necrosis Factor inhibitors (TNFi)
Number of subjects: 1972
Study 39066962 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TNF biologic DMARDs (non-TNFi)
Number of subjects: 1972
Study 39066978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 138
Study 39066978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 39067461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab plus TCS-TCI
Number of subjects: 1728
Study 39067461 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus TCS-TCI
Number of subjects: 1728
Study 39067465 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib-dexamethasone
Number of subjects: 302
Study 39067465 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib-dexamethasone (control group)
Number of subjects: 302
Study 39067464 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEP-BV (cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide) followed by brentuximab vedotin consolidation
Number of subjects: 48